For example, a meta-analysis of the association between ABCG2 421C>A polymorphism and imatinib response in patients with chronic myeloid leukemia revealed that the A allele was significantly associated with an increased rate of overall response [33]. This evidence concerns the gene ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive.